Pharmaceutical

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...

MDaudit’s 2025 Benchmark Report Reveals Ongoing Acceleration of Payer Audits, Troubling Rise in Denials and Outpatient Coding Issues

Annual analysis points to an urgent need to redefine revenue integrity as proactive protection, while strengthening coding integrity and denial...

error: Content is protected !!